Andrea Fiumicelli Appointed as a CEO of Dedalus Group

The Dedalus GroupDedalus Group, leader in Europe and one of the world's leading players in clinical and healthcare information systems supporting clinical professionals and healthcare facilities thanks to a wide portfolio of innovative products, has appointed Andrea Fiumicelli as CEO of the Group.

The manager returns to Italy after several years spent abroad as top manager of large international companies operating in the ICT (Information & Communication Technology) and High Tech sector for "Health Care" and "Life Science" in USA, UK, Germany, Italy, Australia. He will lead the Group's activities in all the countries where it operates and continue to work on the development and digital transformation of the products and services offered by Dedalus.

Graduated in Physics at the University of Genoa, Andrea Fiumicelli has carried out over the years the technological development on a large scale within the rapidly evolving medical-healthcare world and closed important M&A deals.

Before joining Dedalus, he contributed to the birth of DXC Technology (the result of the merger of Computer Science Corporation with Hewlett Packard Enterprise Services) and led, until yesterday, the Health Care and Life Science division. Previously in CSC thanks to the acquisition of iSOFT (where he was CEO and led the merger with IBA Health), he contributed to the creation of the Health Care (HC) and Life Science (LS) segments. In 2005 he contributed to the transformation of Agfa Health Care into a global player in the production of healthcare IT and medical devices.

After completing the acquisition of part of Agfa HealthCare's IT business in the healthcare sector, the Dedalus Group is now one of the most important companies of the world operating in the field of clinical and healthcare information systems with a presence in over 30 countries worldwide, total turnover of approximately 470 million euros and a workforce of over 3,500 professionals.

Andrea Fiumicelli will be responsible of leading the implementation of the corporate strategy based on the operational continuity of the various local companies with a stronger corporate organization.

Andrea Fiumicelli commented: "I'm excited to join the management team of such an excellent company - operating within an industry I have always been passionate about - which was born in Italy but it has become global since a long time. I believe it's fundamental, even more today, to focus on the digital transformation of the healthcare systems which Dedalus is successfully carrying on. This is a new personal challenge for me. I'll come back to Italy, after many years spent living and working abroad, to help Dedalus keep on growing. Following the recent acquisition of Agfa Healthcare's IT business unit, Dedalus has become a European leader and aims to grow further in order to achieve a key role within the innovation and digital transformation of healthcare systems worldwide. I'll work with a high-level team of professionals who represent the real strategic asset of the company, responsible for this very important large-scale technological innovation with the significant enhancement of our precious product portfolio."

Giorgio Moretti, Executive Chairman of Dedalus Group, declared: "I'm proud to welcome such a high-profile manager as Andrea who has showed excellent managerial expertise acquired during many years of work for several big international companies. He is the right man to lead the new shape and ambition of the Group which has become bigger and more structured but it always keeps a special eye to the single specific markets where it operates: first of all Italy, Germany, France, Austria and some other 30 countries across the 5 continents. Our mission and responsibility is to guarantee quality and technological development to our clients. We have become a leader in Europe in the industry of clinical-healthcare information systems and we are among the first players in the world thanks to the significant investments in R&D that we have made in recent years and that we will further increase in the coming years. The deep and systemic knowledge of clinical-healthcare systems declined in products at the state of the art of technology, the excellence of our people and of our new organization will allow Dedalus to express at best the value we can, want and must transfer to our clients."

About Dedalus Group

Founded in Florence in 1982, Dedalus Group is the leading healthcare and diagnostic software provider in Europe and one of the largest in the world. The shareholding structure ensures stability and great financial capacity through the presence of Ardian, the largest private investment company in Europe and 4th in the world.

Starting in 2016, Dedalus has decided to accelerate its expansion strategy by targeting a growing demand for innovative and comprehensive ICT and Clinical transformation solutions. With the acquisition of Agfa Healthcare IT, Dedalus consolidates its leadership as pan-European player in healthcare software industry, with a market leading position in Hospital IT (HCIS) and Diagnostic (DIS) in Germany, Italy and France, with a strong footprint in Austria, Switzerland, Spain, Belgium, China, Brazil and several locations in the Latin America, Middle East and Africa, reaching over 30 different countries. Today Dedalus employs over 3,500 highly skilled resources; it has the largest R&D software team in the sector in Europe with more than 1,100 people. Thanks to its undisputed cutting-edge portfolio of leading the new generation solutions, Dedalus covers the whole spectrum of needs for healthcare operators, supporting over 5000 hospitals and 5000 laboratories around the world.

Most Popular Now

Integrating Care Records is Good. Using …

Opinion Article by Dr Paul Deffley, Chief Medical Officer, Alcidion. A single patient record already exists in the NHS. Or at least, that’s a perception shared by many. A survey of...

AI could Help Pathologists Match Cancer …

A new study by researchers at the Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, and collaborators, suggests that artificial intelligence (AI) could significantly improve how...

Should AI Chatbots Replace Your Therapis…

The new study exposes the dangerous flaws in using artificial intelligence (AI) chatbots for mental health support. For the first time, the researchers evaluated these AI systems against clinical standards...

AI Detects Early Signs of Osteoporosis f…

Investigators have developed an artificial intelligence-assisted diagnostic system that can estimate bone mineral density in both the lumbar spine and the femur of the upper leg, based on X-ray images...

AI Sharpens Pathologists' Interpret…

Pathologists' examinations of tissue samples from skin cancer tumours improved when they were assisted by an AI tool. The assessments became more consistent and patients' prognoses were described more accurately...

AI Tool Detects Surgical Site Infections…

A team of Mayo Clinic researchers has developed an artificial intelligence (AI) system that can detect surgical site infections (SSIs) with high accuracy from patient-submitted postoperative wound photos, potentially transforming...

Meet Your Digital Twin

Before an important meeting or when a big decision needs to be made, we often mentally run through various scenarios before settling on the best course of action. But when...

NHS National Rehabilitation Centre to De…

The new NHS National Rehabilitation Centre will deploy technology to help patients to maintain their independence as they recover from life-changing injuries and illnesses and regain quality of life. Airwave Healthcare...

AI Finds Hundreds of Potential Antibioti…

Snake, scorpion, and spider venom are most frequently associated with poisonous bites, but with the help of artificial intelligence, they might be able to help fight antibiotic resistance, which contributes...

AI Tool Accurately Detects Tumor Locatio…

An AI model trained to detect abnormalities on breast MR images accurately depicted tumor locations and outperformed benchmark models when tested in three different groups, according to a study published...

AI can Accelerate Search for More Effect…

Scientists have used an AI model to reassess the results of a completed clinical trial for an Alzheimer’s disease drug. They found the drug slowed cognitive decline by 46% in...

AI Accurately Classifies Pancreatic Cyst…

Artificial intelligence (AI) models such as ChatGPT are designed to rapidly process data. Using the AI ChatGPT-4 platform to extract and analyze specific data points from the Magnetic Resonance Imaging...